Mannose-binding lectin (MBL) - deficient patients who undergo chemotherapy for a solid tumor might have an increased risk developing febrile neutropenia (FN). We investigated in a prospective cohort study relations between MBL-serum levels and polymorphisms in MBL promotor genotypes (550H/L and 221X/Y) on incidence and severity of FN. Risk of FN was 17.9% in MBL-deficient and 22.5% in MBL-sufficient patients (RR ¼ 0.796, p ¼ 0.45). Median MBL serum levels at baseline were respectively 1.39 mg/mL and 1.09 mg/mL (p ¼ 0.92) in patients with and without FN. In conclusion, serum MBL and MBL genotypes (550H/L and 221X/Y) do not determine the risk for developing FN.

Additional Metadata
Keywords Mannose-binding lectin (MBL), Solid tumors, Febrile neutropenia, MBLgenotype, MBL-deficiency
Persistent URL dx.doi.org/10.1080/07357907.2019.1582660, hdl.handle.net/1765/116827
Journal Cancer Investigation
Citation
Epskamp, C., Goudzwaard, J.A, Fiets, E., Zuetenhorst, J.M., Polee, M.B, van de Geijn, G.J.M, … Hamberg, A.P. (2019). Mannose binding lectin and prediction of risk for chemotherapy induced febrile neutropenia in patients with a solid tumor. Cancer Investigation, 37(3), 156–162. doi:10.1080/07357907.2019.1582660